On October 23, 2024 TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 registration-stage immune-oncology company developing novel technologies to overcome resistance to cancer immunotherapy, reported that TuHURA recently participated at the 2024 Maxim Healthcare Virtual Summit, Presented by Maxim Group LLC (Press release, TuHURA Biosciences, OCT 23, 2024, View Source [SID1234647343]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

As part of the event, Dr. James Bianco, President and Chief Executive Officer of TuHURA participated in the Precision and Immune Oncology panel. To access the webcast replay, sign up to become anM-Vest member.